CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

A bankruptcy court approved the $305M sale of 23andMe to a nonprofit led by Anne Wojcicki, raising questions about data ...

The DNA data of millions of people who used 23andMe's services won't be sold to a pharmaceutical company. A bankruptcy judge ...

A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe’s co-founder ...

The California-based company, which allowed customers to learn about their ancestry by submitting saliva samples in the mail, filed for bankruptcy in March. As part of that process, it's auctioning ...

Anne Wojcicki’s bid to buy 23andMe, the genetic testing company she co-founded nearly 20 years ago, has received the court ...

Genetic testing company 23andMe never hit on a sustainable business model and went bankrupt. Now, it's being sold to a non-profit launched by the co-founder, delaying addressing data privacy concerns.

With several high-profile drugmakers already lining up for manufacturing space, Fujifilm Biotechnologies is on the cusp of ...

The clock is ticking and you've got less than 2 weeks left to file a claim and get part of the 23andMe class-action settlement.

The fine comes as the DNA testing firm, which filed for bankruptcy in March, is set to be sold to a new owner.

A bankruptcy court this week approved the $305 million sale of genetics testing firm 23andMe to a nonprofit organization led ...